Cargando…

Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system

BACKGROUND: Metastatic outgrowth in breast cancer can occur years after a seeming cure. Existing model systems of dormancy are limited as they do not recapitulate human metastatic dormancy without exogenous manipulations and are unable to query early events of micrometastases. METHODS: Here, we desc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wheeler, S E, Clark, A M, Taylor, D P, Young, C L, Pillai, V C, Stolz, D B, Venkataramanan, R, Lauffenburger, D, Griffith, L, Wells, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264444/ https://www.ncbi.nlm.nih.gov/pubmed/25314052 http://dx.doi.org/10.1038/bjc.2014.533

Ejemplares similares

Inflammatory cytokine IL-8/CXCL8 promotes tumour escape from hepatocyte-induced dormancy
por: Khazali, Ahmad S, et al.
Publicado: (2018)

Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin
por: Yates, C C, et al.
Publicado: (2007)

The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy
por: Payne, R E, et al.
Publicado: (2012)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
por: Farace, F, et al.
Publicado: (2011)

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
por: Bellone, S, et al.
Publicado: (2013)

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity
por: Wang, H, et al.
Publicado: (2012)

All-human microphysical model of metastasis therapy
por: Wheeler, Sarah E, et al.
Publicado: (2013)

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
por: Zidan, J, et al.
Publicado: (2005)

Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity
por: Tittarelli, A, et al.
Publicado: (2015)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer
por: Rao, S R, et al.
Publicado: (2017)

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
por: Bedognetti, D, et al.
Publicado: (2013)

Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer
por: Palmieri, C, et al.
Publicado: (2013)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Elevated level of inhibin-α subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer
por: Balanathan, P, et al.
Publicado: (2009)

Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer
por: Kim, J C, et al.
Publicado: (2013)

Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer
por: Salcido, C D, et al.
Publicado: (2010)

Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer
por: Brown, M D, et al.
Publicado: (2010)

Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects
por: Taylor, D D, et al.
Publicado: (2005)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009)

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
por: Frattini, M, et al.
Publicado: (2007)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
por: del Puerto-Nevado, L, et al.
Publicado: (2014)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

The differential effects of statins on the metastatic behaviour of prostate cancer
por: Brown, M, et al.
Publicado: (2012)

Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression
por: Wyler, L, et al.
Publicado: (2014)

Digital pattern recognition-based image analysis quantifies immune infiltrates in distinct tissue regions of colorectal cancer and identifies a metastatic phenotype
por: Angell, H K, et al.
Publicado: (2013)

Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer
por: Santivasi, W L, et al.
Publicado: (2015)

Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
por: Farace, F, et al.
Publicado: (2011)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
por: Saridaki, Z, et al.
Publicado: (2010)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer
por: Landers, K A, et al.
Publicado: (2008)

Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer
por: Vreuls, C P H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ljgb58ictm71bi2tpvqrvv5fag